Opinion|Videos|April 10, 2026
Treatment Adhereance and AE Management With Sevabertinib in HER2-Mutant NSCLC
Author(s)Martin Dietrich, MD, PhD, Ticiana A. Leal, MD
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss toxicity management with TKIs in HER2-mutant non–small cell lung cancer.
Advertisement
Episodes in this series
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss strategies to optimize adherence and manage adverse effects associated with HER2-targeted TKIs. Dietrich outlines common toxicities and the need for proactive monitoring and early intervention. Leal highlights the role of dose modifications and patient education in maintaining treatment continuity and maximizing therapeutic benefit.
Advertisement
Related to this article
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
UCSF experts will present key research at the 31st Society for Neuro-Oncology Annual Meeting.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5